PHNS

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal disorders. The company's lead product, Voquezna (vonoprazan), is a first-in-class potassium-competitive acid blocker (PCAB) designed to provide rapid, potent, and durable acid suppression. Voquezna is currently FDA-approved for the treatment of erosive esophagitis, the relief of heartburn associated with non-erosive GERD, and in combination with antibiotics for the treatment of H. pylori infection. Phathom is actively expanding its clinical pipeline to explore vonoprazan's utility in other acid-related conditions such as eosinophilic esophagitis. The company was founded through a spin-off of assets from Takeda Pharmaceuticals and holds exclusive rights to vonoprazan in the United States, Europe, and Canada.